Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a strong buy.

Additionally, the FDA last week hindered the ability of compounded drugmakers, including HIMS, to sell lower-cost versions of semaglutide, the weight-loss drug that has proliferated widely.

Now dermatologists are increasingly prescribing the drug Rogaine, known generically as minoxidil, in low-dose pills to help ...

Hims' GLP-1 drugs start at $199 a month, while Wegovy and Ozempic cost over $900 a month — though the price many patients pay depends on their insurance. Earlier this month, Hims ran a Super ...

Additionally, the company is witnessing continued success in acquiring customers through more cost-effective channels as awareness of the Hims & Hers brands grows. On the fourth-quarterearnings ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the ...

Hims & Hers (HIMS) stock plunged 27% on Tuesday ... shares also gained after the company announced it was cutting the cost for its GLP-1 weight-loss prescription Zepbound.

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...